Skip to main content

Table 2 Comparison of baseline characteristics between synchronous (N = 144) and metachronous (N = 70) mRCC groups

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

  

Synchronous

Metachronous

P-value

(N = 144)

(N = 70)

Age (years, min-max)

 

59.0 (26.0–81.0)

56.0 (33.0–76.0)

0.232a

Gender

Male

118 (81.9)

48 (68.6)

0.028b

Female

26 (18.1)

22 (31.4)

 

Nephrectomy

Yes

52 (36.6)

69 (100.0)

<.001b

Treatment free interval

≥1 yr

8 (5.6)

48 (68.6)

<.001c

<  1 yr

136 (94.4)

22 (31.4)

 

Anemia

 

111 (77.1)

59 (84.3)

0.221b

Hypercalcemia

 

20 (14.4)

8 (11.6)

0.578b

Neutrophilia

 

21 (15.1)

12 (17.7)

0.639b

Elevated LDH

>×1.5ULN

39 (38.2)

10 (23.3)

0.082b

KPS

>  80

135 (97.1)

69 (100)

0.304c

≤ 80

4 (2.9)

0 (0)

 

Thrombocytosis

> 400 K

18 (12.5)

4 (5.7)

0.125b

First line therapy

Immunotherapy

89 (61.8)

37 (52.9)

0.212b

Targeted therapy

55 (38.2)

33 (47.1)

 

Heng risk

Intermediate

107 (74.3)

64 (91.4)

0.003b

Poor

37 (25.7)

6 (8.6)

 

Tumor (T)

T1 - T2

70 (67.3)

26 (49.1)

0.027b

T3 -T4

34 (32.7)

27 (50.9)

 

Lymph node(N)

N0

49 (47.1)

5 (20.0)

<.001b

N1

25 (24.0)

20 (80.0)

 

Nx

30 (28.9)

0 (0.0)

 

Fuhrman nuclear grade

G1-G2

30 (33)

11 (21.6)

0.151b

G3-G4

61 (67)

40 (78.4)

 

Histology

Clear cell

113 (96.6)

51 (86.4)

0.022c

Non-clear cell

4 (3.4)

8 (13.6)

 

Treatment duration (Month)

3.4 (1.0–70.4)

5.3 (1.0–62.0)

0.058a

Follow-up duration (Month)

81.3 (4.8–141.5)

142.3 (9.4–147.6)

0.005d

Progression free survival (Month, median(95%CI))

4.4 (3.1–5.2)

5.9 (4.1–9.5)

0.044d

Cancer specific survival (Month, median(95%CI))

9.6 (7.4–13.8)

21.3 (15.1–29.3)

<.001d

  1. KPS Karnofsky performance status
  2. aWilcoxon rank sum test, bChi-square test, cFisher exact test, d: Log-rank test